Rockwell Medical, Inc. (RMTI)
RMTI Stock Price Chart
Explore Rockwell Medical, Inc. interactive price chart. Choose custom timeframes to analyze RMTI price movements and trends.
RMTI Company Profile
Discover essential business fundamentals and corporate details for Rockwell Medical, Inc. (RMTI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
IPO Date
27 Jan 1998
Employees
244.00
Website
https://www.rockwellmed.comCEO
Mark Strobeck
Description
Rockwell Medical, Inc., together with its associated companies, operates as a biopharmaceutical firm specializing in treatments for chronic and end-stage kidney disease. The company provides a range of therapies and products aimed at addressing iron deficiency and supporting hemodialysis procedures, serving markets both within the United States and internationally. A key offering includes its Triferic line (Triferic Dialysate and Triferic AVNU), an innovative iron replacement therapy. This therapy is designed to replenish iron and maintain healthy hemoglobin levels in dialysis patients, notably without increasing existing iron stores. Beyond iron management, Rockwell Medical manufactures, sells, and distributes a comprehensive range of hemodialysis concentrates. These include various acid concentrates such as CitraPure (citric), Dri-Sate (dry), and RenalPure (liquid), alongside a dry acid concentrate mixer, and powder bicarbonate concentrates like RenalPure and SteriLyte. These crucial products are vital for sustaining life in dialysis patients by facilitating the removal of toxins and the replacement of essential nutrients in their bloodstream. The company further supplies ancillary items critical for hemodialysis procedures. This extensive catalog comprises blood tubing, fistula needles, dialyzers, pharmaceuticals, specialized component kits, dressings, cleaning agents, filtration salts, and other necessary provisions utilized by hemodialysis providers. Looking to the future, Rockwell Medical is actively developing additional therapeutic candidates. These include treatments for hospitalized individuals suffering from acute heart failure, as well as solutions for home infusion therapy, enabling patients to receive intravenous medications in a home setting. The company primarily serves medium and small-sized dialysis chains, as well as independent dialysis centers. Established in 1996, Rockwell Medical, Inc. maintains its corporate headquarters in Wixom, Michigan.
RMTI Financial Timeline
Browse a chronological timeline of Rockwell Medical, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.24, while revenue estimate is $17.82m.
Stock split effective on 1 Jul 2026
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2026
EPS came in at -$0.40 falling short of the estimated -$0.10 by -300.00%, while revenue for the quarter reached $17.34m , missing expectations by -3.44%.
Earnings released on 26 Mar 2026
EPS came in at -$0.10 falling short of the estimated $0.40 by -125.00%, while revenue for the quarter reached $18.35m , missing expectations by -1.37%.
Earnings released on 12 Nov 2025
EPS came in at -$0.50 falling short of the estimated -$0.40 by -25.00%, while revenue for the quarter reached $15.93m , missing expectations by -1.93%.
Earnings released on 14 Aug 2025
EPS came in at -$0.05 matching the estimated -$0.05, while revenue for the quarter reached $16.07m , missing expectations by -1.60%.
Earnings released on 12 May 2025
EPS came in at -$0.04 surpassing the estimated -$0.30 by +86.67%, while revenue for the quarter reached $18.91m , beating expectations by +8.33%.
Earnings released on 20 Mar 2025
EPS came in at -$0.02 falling short of the estimated $0.02 by -200.00%, while revenue for the quarter reached $24.67m , beating expectations by +4.95%.
Earnings released on 12 Nov 2024
EPS came in at $0.50 surpassing the estimated $0.10 by +400.00%, while revenue for the quarter reached $28.31m , beating expectations by +6.82%.
Earnings released on 12 Aug 2024
EPS came in at $0.01 surpassing the estimated -$0.30 by +103.33%, while revenue for the quarter reached $25.80m , beating expectations by +12.59%.
Earnings released on 14 May 2024
EPS came in at -$0.60 falling short of the estimated -$0.40 by -50.00%, while revenue for the quarter reached $22.68m , beating expectations by +4.48%.
Earnings released on 4 Apr 2024
EPS came in at -$0.50 surpassing the estimated -$0.70 by +28.57%, while revenue for the quarter reached $22.09m , missing expectations by -2.39%.
Earnings released on 14 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$1.00 by +30.00%, while revenue for the quarter reached $23.77m , beating expectations by +4.05%.
Earnings released on 14 Aug 2023
EPS came in at -$1.80 falling short of the estimated -$1.20 by -50.00%, while revenue for the quarter reached $18.08m , beating expectations by +0.02%.
Earnings released on 15 May 2023
EPS came in at -$1.00 surpassing the estimated -$1.60 by +37.50%, while revenue for the quarter reached $19.67m , beating expectations by +2.88%.
Earnings released on 30 Mar 2023
EPS came in at -$2.00 surpassing the estimated -$3.90 by +48.72%, while revenue for the quarter reached $19.31m , beating expectations by +18.48%.
Earnings released on 14 Nov 2022
EPS came in at -$4.00 surpassing the estimated -$4.85 by +17.53%, while revenue for the quarter reached $18.70m , missing expectations by -3.46%.
Earnings released on 15 Aug 2022
EPS came in at -$5.60 surpassing the estimated -$8.10 by +30.86%, while revenue for the quarter reached $18.68m , beating expectations by +11.20%.
Earnings released on 16 May 2022
EPS came in at -$8.40 surpassing the estimated -$9.90 by +15.15%, while revenue for the quarter reached $16.12m , missing expectations by -14.23%.
Stock split effective on 13 May 2022
Shares were split 1 : 11 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 8 Apr 2022
EPS came in at -$0.90 surpassing the estimated -$9.90 by +90.91%, while revenue for the quarter reached $15.30m , missing expectations by -13.32%.
Earnings released on 15 Nov 2021
EPS came in at -$0.88 falling short of the estimated -$0.77 by -14.29%, while revenue for the quarter reached $15.99m , missing expectations by -26.29%.
Earnings released on 16 Aug 2021
EPS came in at -$0.99 falling short of the estimated -$0.88 by -12.50%, while revenue for the quarter reached $15.14m , missing expectations by -16.74%.
RMTI Stock Performance
Access detailed RMTI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
